CLPT

$11.16

Pre-MarketAs of Mar 17, 8:00 PM UTC

ClearPoint Neuro, Inc.

Recent News

Motley Fool
Mar 17, 2026

ClearPoint Neuro (CLPT) Earnings Call Transcript

Joseph Burnett: Thank you. This is one of the largest unmet needs in all of medicine, and we at ClearPoint Neuro, Inc. believe we can play a crucial role in this exciting future. This foundation is made up of four growing product categories, a vetted pipeline of new development programs, an expanded manufacturing footprint, a thoroughly audited quality system, a collection of global regulatory approvals, an expansive IP portfolio, an installed base of more than 150 global centers, and the cash position and investor base to execute on our strategy.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 17, 2026

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -22.73% and +7.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 16, 2026

ClearPoint Neuro Inc (CLPT) Q4 2025 Earnings Report Preview: What To Expect

The consensus estimate for Q4 2025 revenue is $10.05 million, and the earnings are expected to come in at -$0.20 per share. The full year 2025's revenue is expected to be $36.60 million, and the earnings are expected to be -$0.83 per share. More detailed estimate data can be found on the Forecast page.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 9, 2026

ClearPoint Neuro (CLPT) Moves 8.1% Higher: Will This Strength Last?

ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 7, 2026

How The ClearPoint Neuro (CLPT) Investment Story Is Shifting After FDA Feedback And Valuation Cut

ClearPoint Neuro is back in focus after analysts cut their price target from US$28 to US$18, while also lowering their fair value estimate from US$29 to US$24. The move reflects a mix of optimism around more than 60 biopharma partners and six clinical stage intracranial programs, set against higher perceived risk following recent FDA feedback and related share price pressure. As you read on, you will see what is driving this evolving narrative and how to keep track of the moving...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.